Skip to content

Combining natural tissue and blood-derived healing membranes with bone minerals to treat deep gum-related bone loss.

Amniotic membrane and leukocyte platelet-rich fibrin membrane with hydroxyapatite in treating intrabony defects: a randomised controlled trial - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/08/092140
Enrollment
32
Registered
2025-08-01
Start date
Unknown
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K053- Chronic periodontitis

Interventions

Intervention1: Amniotic Membrane with Hydroxyapatite in treating intrabony defects.: The Amniotic Membrane is sourced from Tissue Bank - Tata Memorial and Research Institute, Mumbai, in standard size

Sponsors

Dr Shashwat Asthana
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Probing Pocket Depth less than or equal to 5mm. 2) Clinical Attachment Level 3mm 3) Sites exhibiting evidence of Intrabony Defects of a minimum 3mm dimension as observed through Cone Beam Computed Tomography (CBCT)

Exclusion criteria

Exclusion criteria: 1) Subjects who went through periodontal therapy within the previous year. 2) Subjects taking any medication that can influence the gingival response during healing. 3) Subjects with any systemic disease affecting the periodontium. 4) Pregnant women and lactating mothers. 5) Subjects with any blood dyscrasia or bleeding disorder. 6) Smokers and tobacco chewers. 7) Subjects who cannot perform routine oral hygiene procedures or do not comply with oral hygiene instructions.

Design outcomes

Primary

MeasureTime frame
1. Assessment of Intrabony Defects and Postoperative Bone Fill at Baseline and 6 months postoperatively. 2. Crestel Bone Level at Baseline and 6 Months Postoperatively.Timepoint: 1. Assessment of Intrabony Defects and Postoperative Bone Fill at Baseline and 6 Months Postoperatively. 2. Crestel Bone Level at Baseline and 6 Months Postoperatively.

Secondary

MeasureTime frame
NILTimepoint: NIL

Countries

India

Contacts

Public ContactDr Shashwat Asthana
ellorabhattmadan@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026